<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialResultsOutput hits="1" offset="0" totalResults="1"><Filters total="48"><Filter label="Trial Technologies" name="trialTechnologies" total="4"><FilterOption id="586" count="1" label="Capsule formulation"/><FilterOption id="751" count="1" label="Film coating"/><FilterOption id="585" count="1" label="Oral formulation"/><FilterOption id="762" count="1" label="Small molecule therapeutic"/></Filter><Filter label="Indications" name="indications" total="1"><FilterOption id="33" count="1" label="Atherosclerosis"/></Filter><Filter label="Endpoint Index" name="trialEndpointIndex" total="15"><FilterOption id="9746" count="1" label="Atherosclerosis - Assessment of Vascular Indices or Parameters - Assessment of intima media thickness (IMT)"/><FilterOption id="9777" count="1" label="Atherosclerosis - Assessment of lipid profiles - Assessment of Total Cholesterol"/><FilterOption id="9778" count="1" label="Atherosclerosis - Assessment of lipid profiles - Assessment of Triglycerides"/><FilterOption id="9787" count="1" label="Atherosclerosis - Assessment of lipid profiles - Assessment of apolipoprotein A1 (Apo A1)"/><FilterOption id="9788" count="1" label="Atherosclerosis - Assessment of lipid profiles - Assessment of apolipoprotein B (Apo B)"/><FilterOption id="9782" count="1" label="Atherosclerosis - Assessment of lipid profiles - Assessment of high density lipoprotein cholesterol (HDL-C)"/><FilterOption id="9781" count="1" label="Atherosclerosis - Assessment of lipid profiles - Assessment of low density lipoprotein cholesterol (LDL-C)"/><FilterOption id="2786" count="1" label="Coronary artery disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C-reactive protein (CRP)/high sensitivity C-reactive protein (hs-CRP)"/><FilterOption id="2779" count="1" label="Coronary artery disease - Assessment of Inflammatory &amp; Oxidative Stress Markers"/><FilterOption id="2567" count="1" label="Coronary artery disease - Assessment of Vascular Indices or Parameters - Assessment of Intima Media Thickness /Artery wall thickness"/><FilterOption id="2720" count="1" label="Coronary artery disease - Assessment of lipid profiles - Assessment of Total Cholesterol"/><FilterOption id="2713" count="1" label="Coronary artery disease - Assessment of lipid profiles - High-density lipoprotein cholesterol (HDL-C) levels"/><FilterOption id="2714" count="1" label="Coronary artery disease - Assessment of lipid profiles - Low-density lipoprotein cholesterol (LDL-C) levels"/><FilterOption id="2717" count="1" label="Coronary artery disease - Assessment of lipid profiles - Serum apolipoprotein assessments"/><FilterOption id="2719" count="1" label="Coronary artery disease - Assessment of lipid profiles - Serum triglycerides (TG) level"/></Filter><Filter label="Trial Drug Phase Highest" name="trialDrugPhaseHighest" total="1"><FilterOption id="L" count="1" label="Launched"/></Filter><Filter label="Trial Company Sponsor" name="trialCompaniesSponsor" total="1"><FilterOption id="1058210" count="1" label="Beijing Anzhen Hospital"/></Filter><Filter label="Trial Recruitment Status" name="trialRecruitmentStatus" total="1"><FilterOption id="2" count="1" label="Recruiting"/></Filter><Filter label="Trial Commercially Significant" name="trialIsCommerciallySignificant" total="1"><FilterOption id="YES" count="1" label="Yes"/></Filter><Filter label="Trial Indications Pioneer" name="trialIndicationsPioneer" total="0"/><Filter label="Registry Id" name="trialRegistries" total="1"><FilterOption id="1000" count="1" label="CT.gov"/></Filter><Filter label="Trial Reason for Discontinuation" name="trialReasonForDiscontinuation" total="0"/><Filter label="Active Controls" name="trialActiveControls" total="0"/><Filter label="Exclusion Criteria Index" name="trialExclusionCriteriaIndex" total="11"><FilterOption id="7314" count="1" label="Atherosclerosis - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="7319" count="1" label="Atherosclerosis - Subjects co-morbid with renal disease/disorder"/><FilterOption id="7318" count="1" label="Atherosclerosis - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"/><FilterOption id="7309" count="1" label="Atherosclerosis - Subjects with Co-morbid Conditions"/><FilterOption id="7354" count="1" label="Atherosclerosis - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Hypersensitivity/Contraindications to study medications or its excipients"/><FilterOption id="1760" count="1" label="Coronary artery disease - Subjects co-morbid with hepatobiliary disorders/diseases"/><FilterOption id="1696" count="1" label="Coronary artery disease - Subjects co-morbid with renal disease/disorder"/><FilterOption id="1861" count="1" label="Coronary artery disease - Subjects with Abnormal Laboratory Findings - Abnormal liver function test"/><FilterOption id="1866" count="1" label="Coronary artery disease - Subjects with Abnormal Laboratory Findings - Creatine Kinase(CK) above the Upper Limit of Normal"/><FilterOption id="1787" count="1" label="Coronary artery disease - Subjects with Co-morbid Conditions - Musculoskeletal problems /myopathy /muscular dystrophy /myasthenia gravis"/><FilterOption id="1602" count="1" label="Coronary artery disease - Subjects with Myocardial Infarction (MI)"/></Filter><Filter label="Trial Date Enrollment End By Month" name="trialDateEnrollmentEndByMonth" total="0"/><Filter label="Funder Type" name="trialFunderType" total="2"><FilterOption id="ACA" count="1" label="Academic"/><FilterOption id="CMP" count="1" label="Company"/></Filter><Filter label="Trial Region" name="trialRegions" total="1"><FilterOption id="EAPO" count="1" label="East Asia &amp; Pacific Ocean"/></Filter><Filter label="Patient Segment Index" name="trialPatientSegmentIndex" total="1"><FilterOption id="7247" count="1" label="Atherosclerosis - Subjects with comorbid conditions - Subjects with cardiovascular diseases/disorders"/></Filter><Filter label="Primary Completion Filter by Month" name="trialPrimaryCompletionDateByMonth" total="1"><FilterOption count="1" label="201404"/></Filter><Filter label="Trial Country" name="trialCountries" total="1"><FilterOption id="CN" count="1" label="China"/></Filter><Filter label="Trial Patient Selection" name="trialTermsPatientSelection" total="2"><FilterOption id="EAAAD" count="1" label="Aged Adults (65-79 yrs)"/><FilterOption id="EAMAA" count="1" label="Middle-aged Adults (45-64 yrs)"/></Filter><Filter label="Trial Terms Design" name="trialTermsDesign" total="4"><FilterOption id="SSTINV" count="1" label="Interventional"/><FilterOption id="SIMOPN" count="1" label="Open Label"/><FilterOption id="SISSNG" count="1" label="Single Group Assignment"/><FilterOption id="SIPTRE" count="1" label="Treatment"/></Filter><Filter label="Trial Source" name="trialSources" total="1"><FilterOption id="CTGOV" count="1" label="ClinicalTrials.gov only"/></Filter><Filter label="Trial Actions Secondary Interventions Primary" name="trialActionsSecondaryInterventionsPrimary" total="1"><FilterOption id="71" count="1" label="Antihypercholesterolemic agent"/></Filter><Filter label="Trial Endpoint Achieved" name="trialEndpointsAchieved" total="0"/><Filter label="Endpoint Index Secondary" name="trialEndpointIndexSecondary" total="11"><FilterOption id="9777" count="1" label="Atherosclerosis - Assessment of lipid profiles - Assessment of Total Cholesterol"/><FilterOption id="9778" count="1" label="Atherosclerosis - Assessment of lipid profiles - Assessment of Triglycerides"/><FilterOption id="9787" count="1" label="Atherosclerosis - Assessment of lipid profiles - Assessment of apolipoprotein A1 (Apo A1)"/><FilterOption id="9788" count="1" label="Atherosclerosis - Assessment of lipid profiles - Assessment of apolipoprotein B (Apo B)"/><FilterOption id="9782" count="1" label="Atherosclerosis - Assessment of lipid profiles - Assessment of high density lipoprotein cholesterol (HDL-C)"/><FilterOption id="9781" count="1" label="Atherosclerosis - Assessment of lipid profiles - Assessment of low density lipoprotein cholesterol (LDL-C)"/><FilterOption id="2720" count="1" label="Coronary artery disease - Assessment of lipid profiles - Assessment of Total Cholesterol"/><FilterOption id="2713" count="1" label="Coronary artery disease - Assessment of lipid profiles - High-density lipoprotein cholesterol (HDL-C) levels"/><FilterOption id="2714" count="1" label="Coronary artery disease - Assessment of lipid profiles - Low-density lipoprotein cholesterol (LDL-C) levels"/><FilterOption id="2717" count="1" label="Coronary artery disease - Assessment of lipid profiles - Serum apolipoprotein assessments"/><FilterOption id="2719" count="1" label="Coronary artery disease - Assessment of lipid profiles - Serum triglycerides (TG) level"/></Filter><Filter label="Biomarker" name="trialBiomarkerNames" total="9"><FilterOption id="214" count="1" label="Apolipoprotein A-I"/><FilterOption id="215" count="1" label="Apolipoprotein B-100"/><FilterOption id="7938" count="1" label="Conserved oligomeric Golgi complex subunit 2"/><FilterOption id="153" count="1" label="High-density lipoprotein cholesterol"/><FilterOption id="45" count="1" label="Osteopontin"/><FilterOption id="100" count="1" label="Platelet-activating factor acetylhydrolase"/><FilterOption id="75" count="1" label="Thyroglobulin"/><FilterOption id="133" count="1" label="Total cholesterol"/><FilterOption id="344" count="1" label="Tumor necrosis factor receptor superfamily member 11B"/></Filter><Filter label="Trial Terms Endpoint" name="trialTermsEndpoint" total="1"><FilterOption id="SIEEFC" count="1" label="Efficacy"/></Filter><Filter label="Trial Interventions Primary In Regimen Name Display" name="trialInterventionsPrimaryInRegimenNameDisplay" total="0"/><Filter label="Trial Document Source" name="trialDocumentSource" total="0"/><Filter label="Trial Interventions Primary Alone Name Display" name="trialInterventionsPrimaryAloneNameDisplay" total="1"><FilterOption id="3160" count="1" label="fluvastatin"/></Filter><Filter label="Trial Interventions Control In Regimen Name Display" name="trialInterventionsControlInRegimenNameDisplay" total="0"/><Filter label="Trial Category" name="trialCategory" total="1"><FilterOption id="4" count="1" label="Small molecule"/></Filter><Filter label="Trial Outcome Available" name="trialOutcomesAvailable" total="1"><FilterOption id="NO" count="1" label="No"/></Filter><Filter label="Trial Actions Primary Interventions Primary" name="trialActionsPrimaryInterventionsPrimary" total="1"><FilterOption id="205" count="1" label="HMG CoA reductase inhibitor"/></Filter><Filter label="Trial Company Collaborator" name="trialCompaniesCollaborator" total="1"><FilterOption id="23137" count="1" label="Novartis AG"/></Filter><Filter label="Trial Actions Secondary Interventions Control" name="trialActionsSecondaryInterventionsControl" total="0"/><Filter label="Biomarker Type" name="trialBiomarkerTypes" total="3"><FilterOption id="32" count="1" label="Biochemical"/><FilterOption id="38" count="1" label="Genomic"/><FilterOption id="37" count="1" label="Proteomic"/></Filter><Filter label="Biomarker Role" name="trialBiomarkerRoles" total="1"><FilterOption id="695863716" count="1" label="Therapeutic effect marker"/></Filter><Filter label="Interventions" name="trialInterventions" total="1"><FilterOption id="3160" count="1" label="fluvastatin"/></Filter><Filter label="Endpoint Index Primary" name="trialEndpointIndexPrimary" total="2"><FilterOption id="9746" count="1" label="Atherosclerosis - Assessment of Vascular Indices or Parameters - Assessment of intima media thickness (IMT)"/><FilterOption id="2567" count="1" label="Coronary artery disease - Assessment of Vascular Indices or Parameters - Assessment of Intima Media Thickness /Artery wall thickness"/></Filter><Filter label="Sponsors/Collaborators" name="trialCompanies" total="2"><FilterOption id="1058210" count="1" label="Beijing Anzhen Hospital"/><FilterOption id="23137" count="1" label="Novartis AG"/></Filter><Filter label="Last Changed Date By Day" name="trialDateChangeLastByDay" total="1"><FilterOption count="1" label="2013-09-11"/></Filter><Filter label="Trial Date End By Month" name="trialDateEndByMonth" total="1"><FilterOption count="1" label="201408"/></Filter><Filter label="Trial Date Start By Month" name="trialDateStartByMonth" total="1"><FilterOption count="1" label="201207"/></Filter><Filter label="Trial Phase" name="trialPhase" total="1"><FilterOption id="C4" count="1" label="Phase 4 Clinical"/></Filter><Filter label="Inclusion Criteria Index" name="trialInclusionCriteriaIndex" total="3"><FilterOption id="5725" count="1" label="Atherosclerosis - Subjects co-morbid with cardiovascular disease/disorder"/><FilterOption id="5735" count="1" label="Atherosclerosis - Subjects with Normal/Acceptable Laboratory Criteria"/><FilterOption id="1068" count="1" label="Coronary artery disease - Subjects with Coronary Artery Disease (CAD)"/></Filter><Filter label="Trial Interventions Control Alone Name Display" name="trialInterventionsControlAloneNameDisplay" total="0"/><Filter label="Trial Actions Primary Interventions Control" name="trialActionsPrimaryInterventionsControl" total="0"/><Filter label="Trial Indications Adverse" name="trialIndicationsAdverse" total="0"/></Filters><SearchResults><Trial Id="91022"><Indications><Indication>Atherosclerosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>HMG CoA reductase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihypercholesterolemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Novartis AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Beijing Anzhen Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2013-09-11T00:00:00Z</DateChangeLast><DateEnd>2014-08-31T00:00:00Z</DateEnd><DateStart>2012-07-31T00:00:00Z</DateStart><Identifiers><Identifier>AZYY-XNK-2012001</Identifier><Identifier>FAITH</Identifier><Identifier>NCT01681199</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>fluvastatin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>140</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This study is designed to assess the effect of statin ( fluvastatin ) on atherosclesrosis progression as well as to explore its potential mechanism besides lipid modifying, such as effect on inflammation and vascular calcification.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of Vascular Indices or Parameters - Assessment of intima media thickness (IMT)</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of lipid profiles - Assessment of Total Cholesterol</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of lipid profiles - Assessment of Triglycerides</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of lipid profiles - Assessment of apolipoprotein A1 (Apo A1)</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of lipid profiles - Assessment of apolipoprotein B (Apo B)</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of lipid profiles - Assessment of high density lipoprotein cholesterol (HDL-C)</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of lipid profiles - Assessment of low density lipoprotein cholesterol (LDL-C)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C-reactive protein (CRP)/high sensitivity C-reactive protein (hs-CRP)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Vascular Indices or Parameters - Assessment of Intima Media Thickness /Artery wall thickness</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of lipid profiles - Assessment of Total Cholesterol</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of lipid profiles - High-density lipoprotein cholesterol (HDL-C) levels</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of lipid profiles - Low-density lipoprotein cholesterol (LDL-C) levels</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of lipid profiles - Serum apolipoprotein assessments</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of lipid profiles - Serum triglycerides (TG) level</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>FAITH: Fluvastatin Ameliorates Atherosclerosis Study</TitleDisplay><PatientSegmentTerms><PatientSegment>Atherosclerosis - Subjects with comorbid conditions - Subjects with cardiovascular diseases/disorders</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Apolipoprotein A-I </BiomarkerName><BiomarkerName> Apolipoprotein B-100 </BiomarkerName><BiomarkerName> Conserved oligomeric Golgi complex subunit 2 </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Osteopontin </BiomarkerName><BiomarkerName> Platelet-activating factor acetylhydrolase </BiomarkerName><BiomarkerName> Thyroglobulin </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Tumor necrosis factor receptor superfamily member 11B</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2014-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>25 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Xin Du, PhD</Name></ContactNames></Trial></SearchResults></trialResultsOutput>